Please login to order a test.
Flecainide is used for the treatment and prophylaxis of supraventricular tachycardia, including AV nodal and AV reentrant tachycardia and atrial fibrillation in patients with normal or near-normal left ventricular function.
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Therapeutic: 0.2−1.0 μg/mL
Flecainide is a Class 1C antiarrhythmic drug approved for the suppression of ventricular arrhythmias. The drug is well absorbed orally. Plasma half-life averages 20 hours (range 12 to 27 hours) in adults, although in children it has been reported to be eight hours. Steady-state levels are achieved in three to five days. Since 10% to 50% of the drug is eliminated in the urine as unchanged drug, impaired renal function will significantly prolong the plasma half-life. Clearance of flecainide can be accelerated by phenobarbital and rifampin. There are no significant metabolites of flecainide. Co-administration with digoxin increases serum digoxin by 20%; co-administration with propranolol increases both by 20% in serum and creates an additive pharmacological effect.
Serum or plasma
Transfer separated serum or plasma to a plastic transport tube. Draw immediately prior to next dose unless otherwise instructed.
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|085662||Flecainide (Tambocor(TM)), S||3638-4||085662||Flecainide (Tambocor(TM)), S||ug/mL||3638-4|